se of anti-inflammatory eye drops after laser therapy for glaucoma treatment
- Conditions
- primary open-angle glaucomaunspecified post-procedure eye disorderglaucoma secondary to other eye disordersH40.8
- Registration Number
- RBR-4ttd9yc
- Lead Sponsor
- Hospital Oftalmológico de Brasília
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot yet recruiting
- Sex
- Not specified
- Target Recruitment
- Not specified
Inclusion Criteria
Patients with primary open-angle glaucoma or ocular hypertension or pseudoexfoliative glaucoma or pigmentary glaucoma or pigment dispersion syndrome, with inadequate control of intraocular pressure or intolerance to topical treatment, that will undergo selective laser trabeculoplasty (SLT). Patients approached must be at least 18 years of age on the date of the procedure and be able to undergo post-SLT follow-up for at least 12 months
Exclusion Criteria
Angle-closure glaucoma; Any previous glaucoma surgery; Any previous corneal procedure (refractive surgery, intrastromal rings, corneal transplant); Pregnant women
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the success of selective laser trabeculoplasty (SLT) at the end of follow-up. The definition of success will be a 20% reduction in pre laser baseline intraocular pressure (IOP) and IOP less than 21mmHg. Failure criteria will be: failure to reach previously defined IOP values and need for retreatment, or need for glaucoma surgery during follow-up
- Secondary Outcome Measures
Name Time Method Secondary outcomes will include changes in visual field and visual acuity (VA) and post selective laser trabeculoplasty (SLT) mean deviation (MD). In addition, we will assess predictors of success and complication rate. The pressure reduction obtained with the use of pilocarpine eye drops prior to SLT will be used as a predictor of SLT success